NCT04491604View on ClinicalTrials.gov

Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB

PHASE3CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

August 17, 2020

Primary Completion Date

October 29, 2021

Study Completion Date

January 14, 2022

Conditions
Dystrophic Epidermolysis BullosaRecessive Dystrophic Epidermolysis BullosaDominant Dystrophic Epidermolysis Bullosa
Interventions
BIOLOGICAL

Topical Beremagene Geperpavec

Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein

OTHER

Placebo

Matching masked inactive topical gel

Trial Locations (3)

33146

Pediatric Skin Research, LLC, Coral Gables

92688

Mission Dermatology Center, Rancho Santa Margarita

94305

Stanford University, Stanford

Sponsors
All Listed Sponsors
lead

Krystal Biotech, Inc.

INDUSTRY

NCT04491604 - Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB | Biotech Hunter | Biotech Hunter